Can subcutaneous hormone pellets (testosterone or estrogen) be safely removed?

Can Hormone Pellets Be Removed?

Yes, subcutaneous hormone pellets (testosterone or estrogen) can be surgically removed if medically necessary, though removal is typically reserved for serious complications such as infection, severe local reaction, or life-threatening conditions like hormone-sensitive malignancies. 1

Indications for Pellet Removal

Absolute Indications

• Infection at the implantation site warrants pellet removal, as infection rates range from 0.3% to 6.8% depending on technique and pellet manufacturing 2, 3
• Diagnosis of hormone-sensitive cancer (estrogen-dependent breast cancer or potentially androgen-sensitive malignancies) may require removal, though up to 35% of transgender and gender-diverse individuals would choose to continue hormone therapy even with such a diagnosis 1
• Severe allergic or inflammatory reactions at the implant site that do not resolve with conservative management 4

Relative Indications

• Pellet extrusion occurs in 0.8% to 12% of procedures depending on technique, with the "V" implantation technique showing significantly lower rates (0.8%) compared to standard linear technique (7.5%) 5, 6, 7
• Symptomatic complications including persistent pain, nodules, furuncles, or significant swelling that impair quality of life 4
• Supraphysiologic testosterone levels causing erythrocytosis (hematocrit >54%) that does not respond to phlebotomy, though dose adjustment at next scheduled replacement is typically preferred over early removal 4, 8

Clinical Context for Removal Decisions

Cancer Diagnosis Scenario

• In transgender men diagnosed with estrogen-dependent breast cancer, the decision to remove testosterone pellets must balance cancer outcomes against gender dysphoria and quality of life 1
• Exogenous estradiol in cisgender women promotes estrogen-dependent breast cancer recurrence, suggesting similar concerns may apply to aromatization of testosterone to estrogen 1
• Prospective data on antineoplastic endocrine therapy efficacy in the setting of ongoing gender-affirming hormone therapy are lacking, making evidence-based recommendations challenging 1
• Implanted testosterone pellets at doses used for vasomotor symptoms (much lower than gender-affirming doses) have been safely combined with aromatase inhibitors, but this does not directly translate to higher-dose gender-affirming therapy 1

Infection Management

• Infection requiring antibiotic treatment is associated with a 60% subsequent extrusion rate, suggesting that infected pellets often require removal 6
• The lowest infection rates (0.3%) are achieved with smooth-surfaced pellets free of foreign packaging material and meticulous surgical technique 3

Surgical Removal Technique Considerations

Procedural Factors

• Pellets are implanted subcutaneously in the lateral abdominal wall or hip region, typically 2-4 cm deep 7, 5
• The "V" technique (two tracks emanating from a single incision at 10-15 degrees apart) reduces extrusion and infection rates compared to standard single-track technique 5
• Removal requires local anesthesia and surgical exploration of the implantation track(s), with potential difficulty locating pellets that have migrated or become encapsulated in fibrous tissue

Timing Considerations

• Testosterone pellets deliver stable physiologic concentrations for 4-6 months via zero-order absorption, with peak levels at approximately 1 month followed by gradual decline 4
• Early removal (within the first month) may be more technically feasible before significant fibrous encapsulation occurs, though no published data directly address optimal timing

Alternative Management Strategies

Conservative Approaches First

• For erythrocytosis, therapeutic phlebotomy and dose reduction at next scheduled replacement is preferred over early removal 8, 4
• For minor local reactions (bruising, mild pain, small nodules), observation with anti-inflammatory measures typically suffices 4
• Anticoagulation is not a contraindication to pellet therapy, with only 1.2% hematoma rate even in patients on blood thinners using proper technique 5

Common Pitfalls to Avoid

• Do not attempt removal for minor aesthetic concerns or patient regret without serious medical indication, as surgical exploration carries its own risks of bleeding, infection, and scarring
• Do not assume all pellets can be easily located and removed—migration and fibrous encapsulation may make complete removal technically challenging
• Do not remove pellets in transgender patients with new cancer diagnoses without extensive shared decision-making, as gender dysphoria from hormone withdrawal may severely impact quality of life and mental health 1
• Do not delay removal when infection is present, as 60% of infected implants subsequently extrude and may cause more extensive tissue damage 6

Quality of Life and Mortality Considerations

• For transgender and gender-diverse individuals, gender-affirming hormone therapy may be "life-saving" by reducing depression, anxiety, and suicidality 1
• Forced discontinuation of hormone therapy to treat cancer may worsen gender dysphoria and precipitate mental health crises, requiring careful weighing of cancer mortality risk against quality of life and suicide risk 1
• The overall complication rate for hormone pellet therapy is less than 1% in large series, with 93% continuation rate after two insertions, suggesting most patients do not require removal 2